Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts

NCT06893588 · tracked via the Priya Life Science USA tracker

Sponsor

Vesalio

Phase

Observational

Started

2025-04-14

Last updated

2026-05-27

Condition(s) studied

Cerebral VasospasmAneurysmal Subarachnoid Hemorrhage (aSAH)

Investigational drug(s) / intervention(s)

NEVA VS

NEVA VS: cerebral artery dilation device

Study summary

A multi-center, observational registry study intended to assess the HDE-approved NeVa VS cerebral artery dilation device in patients with symptomatic cerebral vasospasm caused by aneurysmal subarachnoid hemorrhage (aSAH)

Eligibility

Sex

ALL

Min age

22 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Age ≥22 2. Symptomatic cerebral vasospasm secondary to aneurysmal subarachnoid hemorrhage (aSAH) in the internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA), or basilar artery (BA) 3. Vessel dilation procedure was performed with the NeVa VS 4. Subject or legal representative is able and willing to give informed consent within 3 days (72 hours) post-index procedure Exclusion Criteria: * None

Primary outcome measure(s)

Improvement in target vessel diameter following NeVa VS use — Up to 1 hour post procedure

Trial sites (16)

Facility	City	Region	Status
Providence St. Joseph Medical Center	Burbank	California	Recruiting
John Muir Health	Walnut Creek	California	Recruiting
Yale	New Haven	Connecticut	Recruiting
Baptist Health South Florida	Miami	Florida	Recruiting
Wellstar Health System	Marietta	Georgia	Recruiting
Endeavor Health	Evanston	Illinois	Recruiting
Univ Iowa	Iowa City	Iowa	Recruiting
Univ Kentucky	Lexington	Kentucky	Recruiting
MaineHealth	Portland	Maine	Recruiting
Mayo Clinic- Rochester	Rochester	Minnesota	Recruiting
Allegheny Health Network	Pittsburgh	Pennsylvania	Recruiting
Geisinger	Wilkes-Barre	Pennsylvania	Recruiting
Valley Baptist Medical Center- Harlingen	Harlingen	Texas	Recruiting
University of Texas Health Science Center at Houston	Houston	Texas	Recruiting
Uni. of Utah	Salt Lake City	Utah	Recruiting
West Virginia University	Morgantown	West Virginia	Recruiting

Other trials for the same condition

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06893588 on ClinicalTrials.gov ↗ ← All trials in the USA